Literature DB >> 7957521

Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects.

M Rochdi1, A Sabouraud, C Girre, R Venet, J M Scherrmann.   

Abstract

The pharmacokinetics of colchicine were studied in six healthy male and four elderly female volunteers after i.v. and oral administration. Plasma samples were collected over 72 h and assayed for colchicine by a specific and sensitive radioimmunoassay. Plasma concentration-time curves were fitted using a three-compartmental model after i.v. administration of 0.5 mg (healthy volunteers) and 1 mg (elderly group) colchicine. The first distribution half-life (t1/2 lambda 1) was short: 9.2 min in healthy volunteers and 3.0 min in the elderly group; the second distribution half-life (t1/2 lambda 2) was of the same order for both groups, 1.2 h. Plasma elimination half-lives were also in the same range: 30 h for healthy volunteers versus 34 h for the elderly subjects. Mean residence time was also in the same range in the two groups: 27 h in healthy volunteers and 21 h for elderly subjects. The volume of distribution (Vz) was 6.7 l.kg-1 for the healthy group and 6.3 l.kg-1 for the elderly group, while Vss was smaller: 4.2 l.kg-1 for healthy volunteers and 2.9 l.kg-1 for elderly subjects. Total body clearance was 10.5 l.h-1 for healthy and 5.5 l.h-1 for elderly subjects. After oral administration of 1 mg, lag-time was 14 min in healthy volunteers and 11 min in elderly subjects. Maximal plasma concentration was 5.5 ng.ml-1 at 62 min in the healthy group, while in the elderly group Cmax was 12 ng.ml-1 at 87 min. Mean absolute bioavailability of the tablet was the same in both groups, 44% for healthy volunteers and 45% for elderly subjects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957521     DOI: 10.1007/BF00194404

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Pharmacokinetics/bioavailability of colchicine in healthy male volunteers.

Authors:  G Achtert; J M Scherrmann; M O Christen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

2.  Zero-order absorption and linear disposition of oral colchicine in healthy volunteers.

Authors:  G Thomas; C Girre; J M Scherrmann; P Francheteau; J L Steimer
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers.

Authors:  C Girre; G Thomas; J M Scherrmann; J Crouzette; P E Fournier
Journal:  Fundam Clin Pharmacol       Date:  1989       Impact factor: 2.748

4.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

5.  Treatment of pustulosis palmaris et plantaris with oral doses of colchicine.

Authors:  M Takigawa; Y Miyachi; M Uehara; H Tagami
Journal:  Arch Dermatol       Date:  1982-07

6.  Colchicine in the treatment of cirrhosis of the liver.

Authors:  D Kershenobich; F Vargas; G Garcia-Tsao; R Perez Tamayo; M Gent; M Rojkind
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

7.  Long-term evaluation of colchicine in the treatment of scleroderma.

Authors:  D Alarcon-Segovia; F Ramos-Niembro; G Ibanez de Kasep; J Alcocer; R P Tamayo
Journal:  J Rheumatol       Date:  1979 Nov-Dec       Impact factor: 4.666

8.  A fatal overdose with colchicine.

Authors:  Y H Caplan; K G Orloff; B C Thompson
Journal:  J Anal Toxicol       Date:  1980 May-Jun       Impact factor: 3.367

9.  Colchicine kinetics in patients with familial Mediterranean fever.

Authors:  H Halkin; S Dany; M Greenwald; Y Shnaps; M Tirosh
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

10.  Colchicine in acute gout. Reassessment of risks and benefits.

Authors:  W N Roberts; M H Liang; S H Stern
Journal:  JAMA       Date:  1987-04-10       Impact factor: 56.272

View more
  14 in total

1.  Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier.

Authors:  Uwe Tröger; Hartmut Lins; Jean-M Scherrmann; Claus-Werner Wallesch; Stefanie M Bode-Böger
Journal:  BMJ       Date:  2005-09-07

2.  Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same?

Authors:  Hakan Emmungil; Ufuk İlgen; Sezin Turan; Samet Yaman; Orhan Küçükşahin
Journal:  Rheumatol Int       Date:  2019-08-28       Impact factor: 2.631

3.  Colchicine induces autophagy and senescence in lung cancer cells at clinically admissible concentration: potential use of colchicine in combination with autophagy inhibitor in cancer therapy.

Authors:  Surela Bhattacharya; Amlan Das; Satabdi Datta; Arnab Ganguli; Gopal Chakrabarti
Journal:  Tumour Biol       Date:  2016-02-11

Review 4.  Colchicine: old and new.

Authors:  Anastasia Slobodnick; Binita Shah; Michael H Pillinger; Svetlana Krasnokutsky
Journal:  Am J Med       Date:  2014-12-30       Impact factor: 4.965

Review 5.  Update on colchicine and its mechanism of action.

Authors:  Yair Molad
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

Review 6.  Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease.

Authors:  Philip C Robinson; Robert Terkeltaub; Michael H Pillinger; Binita Shah; Vangelis Karalis; Eleni Karatza; David Liew; Massimo Imazio; Jan H Cornel; Peter L Thompson; Mark Nidorf
Journal:  Am J Med       Date:  2021-08-18       Impact factor: 4.965

7.  Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.

Authors:  Arik Dahan; Gordon L Amidon
Journal:  Pharm Res       Date:  2008-12-02       Impact factor: 4.200

Review 8.  Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.

Authors:  Alessandra Soriano; Marco Soriano; Gerard Espinosa; Raffaele Manna; Giacomo Emmi; Luca Cantarini; José Hernández-Rodríguez
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

9.  A rare case report of heavy dose colchicine induced acute kidney injury.

Authors:  Hongzhen Zhong; Zhiqing Zhong; Hongyan Li; Tianbiao Zhou; Weiji Xie
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-30       Impact factor: 2.483

10.  Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure.

Authors:  Christina Yingxian Chen; Matthew A Caporizzo; Kenneth Bedi; Alexia Vite; Alexey I Bogush; Patrick Robison; Julie G Heffler; Alex K Salomon; Neil A Kelly; Apoorva Babu; Michael P Morley; Kenneth B Margulies; Benjamin L Prosser
Journal:  Nat Med       Date:  2018-06-11       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.